Frontiers journals are at the top of citation and impact metrics

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Nutr. | doi: 10.3389/fnut.2018.00127

Efficacy of a therapeutic diet on dogs with signs of cognitive dysfunction syndrome (CDS): A prospective double blinded placebo controlled clinical study

  • 1Nestle Purina Research, United States
  • 2CanCog Technologies, Canada
  • 3Vivocore Inc,, Canada

Cognitive dysfunction syndrome (CDS) is a common condition in senior dogs, which may be analogous to dementia such as Alzheimer’s disease (AD) in people. In humans, AD has been associated with many risk factors such as reduced cerebral glucose metabolism, docosahexaenoic acid (DHA) deficiency, chronic oxidative stress, and chronic inflammation. By targeting some of these risk factors, we have developed two nutritional solutions (medium chain triglyceride, MCT and Brain Protection Blend, BPB) to enhance cognitive function and slow aging-induced cognitive decline. These have been positively evaluated in colony housed senior dogs and cats. The objective of this clinical study was to evaluate the effects of diets with MCTs and the BPB on client-owned dogs with CDS. Participating veterinary clinics screened senior dogs for signs of CDS as determined by a Senior Canine Behavior Questionnaire and a Canine Medical Health Questionnaire. Eighty-seven dogs were randomly enrolled into one of three diet groups with 29 dogs per group: Control, 6.5% MCT oil + BPB (6.5% MCT diet), 9% MCT oil + BPB (9% MCT diet). Diets were fed for a period of 90 days, and each dog’s CDS signs were re-evaluated at day 30 and day 90. All 6 categories of the CDS signs were significantly improved (p <0.05) in the dogs given the 6.5% MCT diet at the end of the 90-day study. Control only improved in 4 out 6 categories. The 9% MCT diet only improved in dogs that accepted the diet. The results from this dog study confirm the benefits of MCT and BPB in managing clinical signs of CDS in dogs. The results support our hypothesis that targeting known risk factors associated with brain aging and AD is able to improve symptoms of CDS in dogs. These data may facilitate the development of similar nutrient blend to manage MCI and AD.  

Keywords: Antioxidants, B vitamins, Arginine, OMEGA - 3 - FATTY ACID, Cognitive dysfunction syndrome, Alzhmeimer's disease, dog, BPB, MCT

Received: 15 Aug 2018; Accepted: 28 Nov 2018.

Edited by:

Odile VILTART, INSERM U894 Centre de Psychiatrie et Neurosciences, France

Reviewed by:

María A. García, Universidad de Concepción, Chile
Mercedes G. López, Centro de Investigación y de Estudios Avanzados (CINVESTAV), Mexico  

Copyright: © 2018 Pan, Landsberg, Mougeot, Kelly, Xu, Bhatnagar, Gardner and Milgram. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Yuanlong Pan, Nestle Purina Research, St Louis, Missouri, United States, Yuanlong.pan@rd.nestle.com